As the U.S. stock market experiences a pullback with major indices like the Dow Jones Industrial Average and S&P 500 closing lower for consecutive sessions, concerns about high valuations in tech stocks have been echoed by Federal Reserve Chair Jerome Powell, adding to the cautious sentiment among investors. In this environment, identifying high-growth tech stocks requires careful consideration of companies that not only show strong fundamentals but also possess innovative capabilities to navigate economic uncertainties and capitalize on emerging opportunities within the technology sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ACADIA Pharmaceuticals | 10.59% | 25.17% | ★★★★★☆ |
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.11% | 31.65% | ★★★★★★ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Workday | 11.29% | 31.64% | ★★★★★☆ |
| Circle Internet Group | 28.59% | 82.71% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.88% | 74.81% | ★★★★★☆ |
| Zscaler | 15.74% | 40.36% | ★★★★★☆ |
Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
CarGurus (CARG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CarGurus, Inc. operates an online automotive platform facilitating vehicle transactions both in the United States and internationally, with a market cap of $3.70 billion.
Operations: The company's primary revenue comes from the U.S. Marketplace segment, generating $778.53 million, while its Digital Wholesale segment contributes $70.64 million.
CarGurus, Inc. has demonstrated a notable turnaround, transitioning from a net loss to reporting a net income of $22.34 million in Q2 2025, up from a significant loss the previous year. This shift is part of an earnings growth forecast at an impressive 24.2% annually, outpacing the US market's expectation of 15.5%. Despite revenue growth projections lagging behind the market at 5.6% per year compared to the US average of 9.8%, CarGurus is capitalizing on strategic partnerships and technological advancements in AI and digital marketing solutions as seen with their new preferred partnership with AutoCanada Inc., enhancing their marketplace visibility and data-driven decision-making capabilities for dealerships across Canada. This focus on technology-driven services and analytics suggests CarGurus is aligning its operations to better meet evolving market demands while also managing recent operational downsizings effectively by winding down less effective segments like CarOffer Transactions Business, projecting cost implications between $14 million to $19 million primarily within this fiscal year.
- Click here to discover the nuances of CarGurus with our detailed analytical health report.
Gain insights into CarGurus' historical performance by reviewing our past performance report.
Cellebrite DI (CLBT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Cellebrite DI Ltd. provides digital intelligence solutions for legally sanctioned investigations across various global regions, with a market cap of $4.36 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $436.73 million.
Cellebrite DI Ltd. has pivoted impressively from a substantial loss, posting a net income of $36.88 million in the first half of 2025, compared to a net loss of $95.18 million in the previous year, signaling robust recovery and operational efficiency. This turnaround is supported by a significant revenue increase to $220.83 million from $185.3 million year-over-year, with projected annual revenue growth at 14.3%, outpacing the US market average of 9.8%. The company's strategic leadership changes, including appointing Thomas E. Hogan as CEO and David Barter as CFO, are poised to further drive innovation and market expansion in their tech segments, underlined by their recent guidance forecasting an annualized revenue range between $465 million to $475 million for 2025. The firm’s commitment to R&D is evident with expenses aligning closely with industry demands for advanced software solutions; this focus is expected to sustain long-term growth beyond current projections of becoming profitable within three years—a testament not only to its recovery trajectory but also its potential in high-growth tech sectors globally.
- Take a closer look at Cellebrite DI's potential here in our health report.
Review our historical performance report to gain insights into Cellebrite DI's's past performance.
Dynavax Technologies (DVAX)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Dynavax Technologies Corporation is a commercial stage biopharmaceutical company that develops and commercializes vaccines both in the United States and internationally, with a market cap of $1.12 billion.
Operations: Dynavax focuses on the discovery, development, and commercialization of novel vaccines, generating $316.27 million in revenue.
Dynavax Technologies has demonstrated a promising trajectory with its innovative Z-1018 shingles vaccine, showing favorable results against the established Shingrix. This progress is underpinned by a robust increase in HEPLISAV-B net product revenue, now expected to reach up to $325 million for 2025, reflecting strong performance. Furthermore, the company's recent earnings underscore its growth potential; second-quarter revenue surged to $95.44 million from $73.8 million year-over-year, coupled with a net income rise to $18.72 million from $11.39 million. These financial achievements are complemented by strategic share repurchases totaling $197.32 million since last November, enhancing shareholder value and affirming Dynavax's commitment to growth amidst competitive market pressures.
Taking Advantage
- Discover the full array of 66 US High Growth Tech and AI Stocks right here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Cellebrite DI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com